Aspire Biopharma Holdings, Inc.(ASBP)Earnings, Financials & Key Ratios

ASBP•NASDAQ

$5.61

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryDiagnostics and Omics Tools

AboutAspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.Show more

Revenue$6K
EBITDA-$19M-66.2%
Net Income-$24M-95.3%
EPS (Diluted)-16.38+9.9%
Gross Margin-1.87%
EBITDA Margin-312016.95%
Operating Margin-312016.95%
Net Margin-394725.06%

ASBP Price & Volume

Aspire Biopharma Holdings, Inc. (ASBP) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operational Burn Threatens Corporate Solvency

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Imminent insolvency and dilution

Key Thesis Takeaways

Aspire Biopharma Holdings remains in a precarious pre-commercial state, characterized by negligible revenue generation and a total lack of economies of scale.
The company's reliance on external financing to cover operating expenses, which consistently dwarf its $28.4K quarterly revenue, suggests an unsustainable business model.
Investors should monitor the critical liquidity shortfall, as the firm's negative equity position and minimal cash reserves indicate a high probability of further dilutive capital raises or insolvency.

Verdict Logic

the company's current ratio of 0.17 and negative equity of $6.4M suggest an imminent risk of insolvency that outweighs any potential speculative upside.

ASBP Growth Metrics

Aspire Biopharma Holdings, Inc. (ASBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM54.78%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM73.23%

Return on Capital

10 Years-11.91%

5 Years-11.91%

3 Years-17.54%

Last Year-

ASBP Recent Earnings

Aspire Biopharma Holdings, Inc. (ASBP) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

Q2 2026Latest

May 15, 2026

Metric

Actual

Est

EPS

$20.57

—

Rev

$28,353

—

Q2 2026

Mar 30, 2026

Metric

Actual

Est

EPS

$3.15

—

Rev

$4,261

—

Q4 2025

Nov 14, 2025

Metric

Actual

Est

EPS

$0.04

—

Rev

$1,941

—

Q3 2025

Aug 13, 2025

Metric

Actual

Est

EPS

$0.04

—

Rev

—

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 15, 2026	$20.57	$28,353
Q2 2026	Mar 30, 2026	$3.15	$4,261
Q4 2025	Nov 14, 2025	$0.04	$1,941
Q3 2025	Aug 13, 2025	$0.04	—

Based on last 12 quarters of dataView full earnings history →

Latest ASBP News

Recent stock market news and headlines for Aspire Biopharma Holdings, Inc. (ASBP)

Accesswire·Jun 24, 2026

Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

The brand expands nationwide distribution on Amazon, delivering a waterless, rapid-dissolve 50 mg caffeine powder built for active, on-the-go lifestyles. ESTERO, FL / ACCESS Newswire / June 24, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC today announced the nationwide Amazon launch of its innovative BUZZ BOMB™ 50mg caffeine stick packs.

GlobeNewsWire·Jun 17, 2026

Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th

ESTERO, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- Aspire Biopharma Holdings, Inc.'s (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that it will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 25th, 2026.

Peers Comparison

Key metrics vs top competitors for Aspire Biopharma Holdings, Inc. (ASBP)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
ASBPAspire Biopharma Holdings, Inc.Current	$5.61	$8.39M	-0.34	—	-394725.06%	—	—
CRBPCorbus Pharmaceuticals Holdings, Inc.	$9.38	$117.58M	-1.59	—	—	-70.89%	—
YCBDcbdMD, Inc.	$0.74	$7.75M	-0.68	-1.5%	-13.29%	-33.59%	—
XXII22nd Century Group, Inc.	$4.36	$1.5M	-0.08	-40.66%	-44.9%	-25.03%	—
ATAIAtai Beckley N.V	$5.19	$1.91B	-1.78	1227.6%	-19019.44%	-366.21%	—
CMPSCOMPASS Pathways plc	$12.99	$1.25B	-4.22	—	—	-151.02%	—

Compare ASBP vs Peers

Aspire Biopharma Holdings, Inc. (ASBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CRBP

Most directly comparable listed peer for ASBP.

Scale Benchmark

vs MNMD

Larger-name benchmark to compare ASBP against a more recognizable public peer.

Peer Set

Compare Top 5

vs CRBP, YCBD, XXII, ATAI

ASBP SEC Filings & Documents

Aspire Biopharma Holdings, Inc. (ASBP) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 14, 2026·SEC

Material company update

Apr 20, 2026·SEC

Material company update

Apr 16, 2026·SEC

10-K Annual Reports

FY 2026

Mar 30, 2026·SEC

FY 2025

Apr 7, 2025·SEC

FY 2024

Mar 11, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 15, 2026·SEC

FY 2025

Nov 14, 2025·SEC

FY 2025

Aug 13, 2025·SEC

Get notified when ASBP posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

ASBP Frequently Asked Questions

Aspire Biopharma Holdings, Inc. (ASBP) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Aspire Biopharma Holdings, Inc.'s revenue?

Aspire Biopharma Holdings, Inc. (ASBP) reported $0.0M in revenue for fiscal year 2025.

Is ASBP profitable?

Aspire Biopharma Holdings, Inc. (ASBP) reported a net loss of $11.8M for fiscal year 2025.

Dividend & Returns

What is Aspire Biopharma Holdings, Inc.'s free cash flow?

Aspire Biopharma Holdings, Inc. (ASBP) had negative free cash flow of $6.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ASBP back in 2021?

Total return calculator · dividends reinvested · 5+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 15, 2026

$20.57

$28,353

Q2 2026

Mar 30, 2026

$3.15

$4,261

Q4 2025

Nov 14, 2025

$0.04

$1,941

Q3 2025

Aug 13, 2025

$0.04

—

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

ASBPAspire Biopharma Holdings, Inc.Current

$5.61

$8.39M

-0.34

—

-394725.06%

—

CRBPCorbus Pharmaceuticals Holdings, Inc.

$9.38

$117.58M

-1.59

—

-70.89%

—

YCBDcbdMD, Inc.

$0.74

$7.75M

-0.68

-1.5%

-13.29%

-33.59%

—

XXII22nd Century Group, Inc.

$4.36

$1.5M

-0.08

-40.66%

-44.9%

-25.03%

—

ATAIAtai Beckley N.V

$5.19

$1.91B

-1.78

1227.6%

-19019.44%

-366.21%

—

CMPSCOMPASS Pathways plc

$12.99

$1.25B

-4.22

—

-151.02%

—